Superior performance of aptamer in tumor penetration over antibody: Implication of aptamer-based theranostics in solid tumors

Theranostics

Volumn 5, Issue 10, 2015, Pages 1083-1097

  Xiang, Dongxi ^a   Zheng, Conglong ^b   Zhou, Shu Feng ^c   Qiao, Shuxi ^d   Tran, Phuong Ha Lien ^a   Pu, Chunwen ^e   Li, Yong ^f   Kong, Lingxue ^a   Kouzani, Abbas Z ^a   Lin, Jia ^g   Liu, Ke ^g   Li, Lianhong ^h   Shigdar, Sarah ^a   Duan, Wei ^a  

^a DEAKIN UNIVERSITY   (Australia)

^b DALIAN UNIVERSITY   (China)

^c UNIVERSITY OF SOUTH FLORIDA   (United States)

^d UNIVERSITY OF ARIZONA   (United States)

^e Dalian 6th People s Hospital   (China)

^f UNIVERSITY OF NEW SOUTH WALES   (Australia)

^g SICHUAN UNIVERSITY   (China)

^h DALIAN MEDICAL UNIVERSITY   (China)

Author keywords

Aptamer; Targeted tumor therapeutics; Tumor penetration

Indexed keywords

ANTINEOPLASTIC AGENT; APTAMER; EPITHELIAL CELL ADHESION MOLECULE; EPITHELIAL CELL ADHESION MOLECULE ANTIBODY; EPITHELIAL CELL ADHESION MOLECULE APTAMER; MACROGOL; UNCLASSIFIED DRUG; MONOCLONAL ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CANCER THERAPY; COLORECTAL CANCER; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG BINDING; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG PENETRATION; DRUG RETENTION; DRUG UPTAKE; FEMALE; HUMAN; HUMAN CELL; IMAGING; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PARTICLE SIZE; SOLID TUMOR; TUMOR XENOGRAFT; ANIMAL; CHEMISTRY; COMPARATIVE STUDY; DEVICES; DRUG DELIVERY SYSTEM; NONOBESE DIABETIC MOUSE; PROCEDURES; SCID MOUSE; THERANOSTIC NANOMEDICINE; TISSUE DISTRIBUTION; TUMOR CELL LINE; XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL; APTAMERS, NUCLEOTIDE; CELL LINE, TUMOR; DRUG DELIVERY SYSTEMS; FEMALE; HUMANS; MICE; MICE, INBRED NOD; MICE, SCID; THERANOSTIC NANOMEDICINE; TISSUE DISTRIBUTION; TRANSPLANTATION, HETEROLOGOUS;

EID: 84945928635     PISSN: None     EISSN: 18387640     Source Type: Journal    
DOI: 10.7150/thno.11711     Document Type: Article

References (64)

1. Muchekehu R, Liu D, Horn M, et al. The Effect of Molecular Weight, PK, and Valency on Tumor Biodistribution and Efficacy of Antibody-Based Drugs. Transl Oncol 2013; 6 (5):562-72.
2. Tunggal JK, Cowan DS, Shaikh H, Tannock IF. Penetration of anticancer drugs through solid tissue: a factor that limits the effectiveness of chemotherapy for solid tumors. Clin Cancer Res 1999; 5 (6):1583-6.
3. Primeau AJ, Rendon A, Hedley D, Lilge L, Tannock IF. The distribution of the anticancer drug Doxorubicin in relation to blood vessels in solid tumors. Clin Cancer Res 2005; 11 (24 Pt 1):8782-8.
4. O'Connor ML, Xiang D, Shigdar S, et al. Cancer stem cells: A contentious hypothesis now moving forward. Cancer Lett 2014; 344 (2):180-7.
5. Minchinton AI, Tannock IF. Drug penetration in solid tumours. Nat Rev Cancer 2006; 6 (8):583-92.
6. Brown JM, Giaccia AJ. The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer Res 1998; 58 (7):1408-16.
7. Leu AJ, Berk DA, Lymboussaki A, Alitalo K, Jain RK. Absence of functional lymphatics within a murine sarcoma: a molecular and functional evaluation. Cancer Res 2000; 60 (16):4324-7.
8. Heldin C-H, Rubin K, Pietras K, Ostman A. High interstitial fluid pressure - an obstacle in cancer therapy. Nat Rev Cancer 2004; 4 (10):806-13.
9. Brown E, McKee T, diTomaso E, et al. Dynamic imaging of collagen and its modulation in tumors in vivo using second-harmonic generation. Nat Med 2003; 9 (6):796-800.
10. Zeng Z, Parekh P, Li Z, Shi Z-Z, Tung C-H, Zu Y. Specific and sensitive tumor imaging using biostable oligonucleotide aptamer probes. Theranostics 2014; 4 (9):945-52.
11. Thurber GM, Schmidt MM, Wittrup KD. Factors determining antibody distribution in tumors. Trends Pharmacol Sci 2008; 29 (2):57-61.
12. Waldmann TA, Morris JC. Development of antibodies and chimeric molecules for cancer immunotherapy. Adv Immunol 2006; 90: 83-131.
13. Boyiadzis M, Foon KA. Approved monoclonal antibodies for cancer therapy. Expert Opin Biol Ther 2008; 8 (8):1151-8.
14. Zahnd C, Kawe M, Stumpp MT, et al. Efficient tumor targeting with high-affinity designed ankyrin repeat proteins: effects of affinity and molecular size. Cancer Res 2010; 70 (4):1595-605.
15. Huo S, Ma H, Huang K, et al. Superior penetration and retention behavior of 50nm gold nanoparticles in tumors. Cancer Res 2013; 73 (1):319-30.
16. Adams GP, Schier R, McCall AM, et al. High affinity restricts the localization and tumor penetration of single-chain fv antibody molecules. Cancer Res 2001; 61 (12):4750-5.
17. Dennis MS, Jin H, Dugger D, et al. Imaging tumors with an albumin-binding Fab, a novel tumor-targeting agent. Cancer Res 2007; 67 (1):254-61.
18. Cobleigh MA, Vogel CL, Tripathy D, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999; 17 (9):2639-48.
19. Xiang D, Shigdar S, Qiao G, et al. Nucleic Acid Aptamer-Guided Cancer Therapeutics and Diagnostics: the Next Generation of Cancer Medicine. Theranostics 2015; 5 (1):23-42.
20. Hicke BJ, Stephens AW, Gould T, et al. Tumor targeting by an aptamer. J Nucl Med 2006; 47 (4):668-78.
21. Watson SR, Chang YF, O'Connell D, Weigand L, Ringquist S, Parma DH. Anti-L-selectin aptamers: binding characteristics, pharmacokinetic parameters, and activity against an intravascular target in vivo. Antisense Nucleic Acid Drug Dev 2000; 10 (2):63-75.
22. Shi H, He X, Wang K, et al. Activatable aptamer probe for contrast-enhanced in vivo cancer imaging based on cell membrane protein-triggered conformation alteration. Proc Natl Acad Sci U S A 2011; 108 (10):3900-5.
23. Shi H, Cui W, He X, et al. Whole cell-SELEX aptamers for highly specific fluorescence molecular imaging of carcinomas in vivo. PLoS One 2013; 8 (8):e70476.
24. Scaggiante B, Dapas B, Farra R, et al. Aptamers as targeting delivery devices or anti-cancer drugs for fighting tumors. Curr Drug Metab 2013; 14 (5):565-82.
25. Pei X, Zhang J, Liu J. Clinical applications of nucleic acid aptamers in cancer. Mol Clin Oncol 2014; 2 (3):341-8.
26. Choi I-K, Strauss R, Richter M, Yun C-O, Lieber A. Strategies to increase drug penetration in solid tumors. Front Oncol 2013; 3: 193.
27. Pickl M, Ries CH. Comparison of 3D and 2D tumor models reveals enhanced HER2 activation in 3D associated with an increased response to trastuzumab. Oncogene 2009; 28 (3):461-8.
28. Ong S-M, Zhao Z, Arooz T, et al. Engineering a scaffold-free 3D tumor model for in vitro drug penetration studies. Biomaterials 2010; 31 (6):1180-90.
29. Chushak Y, Stone MO. In silico selection of RNA aptamers. Nucleic Acids Res 2009; 37 (12):e87.
30. June CH, Blazar BR, Riley JL. Engineering lymphocyte subsets: tools, trials and tribulations. Nat Rev Immunol 2009; 9 (10):704-16.
31. Woloszynska-Read A, James SR, Song C, Jin B, Odunsi K, Karpf AR. BORIS/CTCFL expression is insufficient for cancer-germline antigen gene expression and DNA hypomethylation in ovarian cell lines. Cancer Immun 2010; 10: 6.
32. Wang HH, Xu G, Vonner AJ, Church G. Modified bases enable high-efficiency oligonucleotide-mediated allelic replacement via mismatch repair evasion. Nucleic Acids Res 2011; 39 (16):7336-47.
33. Li N, Ebright JN, Stovall GM, et al. Technical and biological issues relevant to cell typing with aptamers. J Proteome Res 2009; 8 (5):2438-48.
34. Lee CM, Tannock IF. The distribution of the therapeutic monoclonal antibodies cetuximab and trastuzumab within solid tumors. BMC Cancer 2010; 10: 255.
35. Rudnick SI, Lou J, Shaller CC, et al. Influence of affinity and antigen internalization on the uptake and penetration of Anti-HER2 antibodies in solid tumors. Cancer Res 2011; 71 (6):2250-9.
36. Fujimori K, Covell DG, Fletcher JE, Weinstein JN. Modeling analysis of the global and microscopic distribution of immunoglobulin G, F(ab')2, and Fab in tumors. Cancer Res 1989; 49 (20):5656-63.
37. Fujimori K, Covell DG, Fletcher JE, Weinstein JN. A modeling analysis of monoclonal antibody percolation through tumors: a binding-site barrier. J Nucl Med 1990; 31 (7):1191-8.
38. Shigdar S, Lin J, Yu Y, Pastuovic M, Wei M, Duan W. RNA aptamer against a cancer stem cell marker epithelial cell adhesion molecule. Cancer Sci 2011; 102 (5):991-8.
39. Hussain S, Pluckthun A, Allen TM, Zangemeister-Wittke U. Antitumor activity of an epithelial cell adhesion molecule targeted nanovesicular drug delivery system. Mol Cancer Ther 2007; 6 (11):3019-27.
40. Zangemeister-Wittke U. Antibodies for targeted cancer therapy -- technical aspects and clinical perspectives. Pathobiology 2005; 72 (6):279-86.
41. Shigdar S, Qiao L, Zhou S-F, et al. RNA aptamers targeting cancer stem cell marker CD133. Cancer Lett 2013; 330 (1):84-95.
42. Perche F, Patel NR, Torchilin VP. Accumulation and toxicity of antibody-targeted doxorubicin-loaded PEG-PE micelles in ovarian cancer cell spheroid model. J Control Release 2012; 164 (1):95-102.
43. Santini MT, Rainaldi G. Three-dimensional spheroid model in tumor biology. Pathobiology 1999; 67 (3):148-57.
44. Guhlke S, Famulok M, Biersack HJ. Aptamares: a novel class of radiopharmaceutical with diagnostic and therapeutic potential. Eur J Nucl Med Mol Imaging 2003; 30 (11):1441-3.
45. Zhu H, Li J, Zhang XB, Ye M, Tan W. Nucleic Acid aptamer-mediated drug delivery for targeted cancer therapy. ChemMedChem 2015; 10 (1):39-45.
46. Choi HS, Liu W, Misra P, et al. Renal clearance of quantum dots. Nat Biotechnol 2007; 25 (10):1165-70.
47. Jain RK. Barriers to drug delivery in solid tumors. Sci Am 1994; 271 (1):58-65.
48. Huang K, Ma H, Liu J, et al. Size-dependent localization and penetration of ultrasmall gold nanoparticles in cancer cells, multicellular spheroids, and tumors in vivo. ACS Nano 2012; 6 (5):4483-93.
49. Tang L, Gabrielson NP, Uckun FM, Fan TM, Cheng J. Size-dependent tumor penetration and in vivo efficacy of monodisperse drug-silica nanoconjugates. Mol Pharm 2013; 10 (3):883-92.
50. Huo S, Ma H, Huang K, et al. Superior penetration and retention behavior of 50nm gold nanoparticles in tumors. Cancer Res 2013; 73 (1):319-30.
51. Das M, Mohanty C, Sahoo SK. Ligand-based targeted therapy for cancer tissue. Expert Opin Drug Deliv 2009; 6 (3):285-304.
52. White RR, Sullenger BA, Rusconi CP. Developing aptamers into therapeutics. J Clin Invest 2000; 106 (8):929-34.
53. McLaughlin PM, Kroesen BJ, Harmsen MC, de Leij LF. Cancer immunotherapy: insights from transgenic animal models. Crit Rev Oncol Hematol 2001; 40 (1):53-76.
54. Oberneder R, Weckermann D, Ebner B, et al. A phase I study with adecatumumab, a human antibody directed against epithelial cell adhesion molecule, in hormone refractory prostate cancer patients. Eur J. Cancer 2006; 42 (15):2530-8.
55. Sutherland R, Buchegger F, Schreyer M, Vacca A, Mach JP. Penetration and binding of radiolabeled anti-carcinoembryonic antigen monoclonal antibodies and their antigen binding fragments in human colon multicellular tumor spheroids. Cancer Res 1987; 47 (6):1627-33.
56. Schmidt M, Scheulen ME, Dittrich C, et al. An open-label, randomized phase II study of adecatumumab, a fully human anti-EpCAM antibody, as monotherapy in patients with metastatic breast cancer. Ann Oncol 2010; 21 (2):275-82.
57. Schwartzberg LS. Clinical experience with edrecolomab: a monoclonal antibody therapy for colorectal carcinoma. Crit Rev Oncol Hematol 2001; 40 (1):17-24.
58. Juweid M, Neumann R, Paik C, et al. Micropharmacology of monoclonal antibodies in solid tumors: direct experimental evidence for a binding site barrier. Cancer Res 1992; 52 (19):5144-53.
59. Shigdar S, Macdonald J, O'Connor M, et al. Aptamers as theranostic agents: modifications, serum stability and functionalisation. Sensors (Basel) 2013; 13 (10):13624-37.
60. Fracasso G, Colombatti M. Effect of therapeutic macromolecules in spheroids. Crit Rev Oncol Hematol 2000; 36 (2-3):159-78.
61. Kinahan PE, Fletcher JW. Positron emission tomography-computed tomography standardized uptake values in clinical practice and assessing response to therapy. Semin Ultrasound CT MR 2010; 31 (6):496-505.
62. Baker JHE, Lindquist KE, Huxham LA, Kyle AH, Sy JT, Minchinton AI. Direct visualization of heterogeneous extravascular distribution of trastuzumab in human epidermal growth factor receptor type 2 overexpressing xenografts. Clin Cancer Res 2008; 14 (7):2171-9.
63. Jones PL, Gallagher BM, Sands H. Autoradiographic analysis of monoclonal antibody distribution in human colon and breast tumor xenografts. Cancer Immunol Immunother 1986; 22 (2):139-43.
64. Yokota T, Milenic DE, Whitlow M, Schlom J. Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms. Cancer Res 1992; 52 (12):3402-8.